A Phase I/II Imaging Study of 1-a-D-(5-deoxy-5-[18]F-fluoroarabinofuranosyl)-2-nitroimidazole ([18]F-FAZA) in Patients With Known Squamous Cell Carcinoma of the Head & Neck, Small Cell and Non-Small Cell Carcinoma of the Lung, Lymphoma, Glioblastoma Multiforme, Neuroendocrine Tumours or Renal Cell Carcinoma

This is a diagnostic study that focuses on a specific type of imaging called 18F-FAZA PET scan. The study involves patients who have been diagnosed with certain types of cancer, including squamous cell carcinoma of the Head & Neck, small cell and non-small cell carcinoma of the lung, lymphoma, glioblastoma multiforme, neuroendocrine tumors, or renal cell carcinoma. The main goal of this study is to ensure the safety of 18F-FAZA, a substance used in the imaging process, and to understand how it spreads within the body. This research is important as it could potentially improve the way these cancers are diagnosed and treated. The study consists of two phases. In the first phase, patients will undergo a single 18F-FAZA PET scan. Their vital signs, blood test results, and any adverse events will be carefully monitored before the injection and after the imaging. In the second phase, patients will receive three 18F-FAZA PET scans: one before treatment, one during the middle of the treatment, and one after the treatment. The study will examine where the 18F-FAZA goes in the body and how much is taken up by normal and abnormal tissues.